



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/972,546	10/06/2001	Stephen M. Strittmatter	A116 US	4440

7590 02/27/2003

JAMES F. HALEY  
c/o FISH & NEAVE  
1251 AVENUE OF THE AMERICAS- 50th FLOOR  
NEW YORK, NY 10020

EXAMINER	
NICHOLS, CHRISTOPHER J	
ART UNIT	PAPER NUMBER

1647

DATE MAILED: 02/27/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/972,546	STRITTMATTER ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Christopher Nichols, Ph.D.	1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 26 February 2002.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) 1-30 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-30 are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

- 12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.
- 4) Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-10 and 22 drawn to a method for producing a polypeptide comprising an isolated **nucleic acid molecule**, vectors, cells, comprising the same, classified in class 536, subclass 23.1, for example.
  - II. Claims 11-21 and 24 drawn to an isolated **polypeptide** and pharmaceutical compositions comprising the same, classified in class 514, subclass 2, for example.
  - III. Claims 23 and 25 drawn to an **antibody** immunospecific for a polypeptide, pharmaceutical compositions, and kits comprising the same, classified in class 530, subclass 387.1, for example.
  - IV. Claim 26, drawn to a method of decreasing inhibition of axonal growth of a CNS neuron, wherein said method comprises contacting the neuron with an effective amount of a **polypeptide**, classified in class 514, subclass 2, for example.
  - V. Claim 27, drawn to a method of treating a central nervous system disease, disorder, or injury, wherein said method comprises administering to a mammal an effective amount of a **polypeptide**, classified in class 514, subclass 2, for example.
  - VI. Claim 28, drawn to a method of decreasing inhibition of axonal growth of a CNS neuron, wherein said method comprises contacting the neuron with an effective amount of an **antibody**, classified in class 424, subclass 130.1, for example.

- VII. Claim 29, drawn to a method of treating a central nervous system disease, disorder, or injury, wherein said method comprises administering to a mammal an effective amount of an **antibody**, classified in class 424, subclass 130.1, for example.
- VIII. Claim 30, drawn to a method of identifying a **molecule** that binds a polypeptide, classification dependent upon structure of agent.

2. The inventions are distinct, each from the other because of the following reasons:

3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions I, IV, V, VI, VII, and VIII are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention I requires search and consideration of recombinately producing a polypeptide, which is not required by any of the other Inventions. Invention IV requires search and consideration of using a polypeptide to decrease inhibition of axonal growth of a CNS neuron, which is not required by any of the other Inventions. Invention V requires search and consideration of using a polypeptide to treat a CNS disease, disorder, or injury, which is not required by any of the other Inventions. Invention VI requires search and consideration of using an antibody to decrease inhibition of axonal growth of a CNS neuron, which is not required by any of the other Inventions. Invention VII requires search and consideration of using an antibody to treat a CNS disease, disorder, or injury, which is not required by any of the other Inventions. Invention VIII requires search and

Art Unit: 1647

consideration of identifying a molecule which binds a polypeptide, which is not required by any of the other Inventions.

4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions II and III are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The polypeptide of Invention II can be used in materially different methods other than to make the antibody of Invention III such as therapeutic methods. Although the antibody of Invention III can be used to obtain the polypeptide of Invention II it can also be used in materially different methods, such as in various diagnostic (e.g., as a probe in immunoassays or immunochromatography), or therapeutic methods.

5. Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the polypeptide can be made through a materially different process such as isolation from natural sources or chemical synthesis.

6. Inventions II and each of IV, V, and VIII are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that

product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The polypeptide of Invention II can be used to isolate receptors.

7. Inventions III and each of VI and VII are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The antibody of Invention III can be used to isolate the polypeptides.

8. Inventions II and each of VI and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions II and each of VI and VII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions VI and VII do not recite the use or production of the polypeptides of Invention II.

9. Inventions III and each of IV, V, and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions III and each of IV, V, and VIII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed

Art Unit: 1647

methods of Inventions IV, V, and VIII do not recite the use or production of the antibodies of Invention III.

**10. FURTHERMORE, restriction to one of the following inventions is required under 35 U.S.C. 121:**

- A. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 2.
- B. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 4.
- C. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 5.
- D. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 11.
- E. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 14.
- F. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 17.
- G. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 18.
- H. Claims 1-30, each in part, as the inventions pertain to SEQ ID NO: 19.

11. The inventions are distinct, each from the other because of the following reasons:

12. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different products, restriction is deemed to be proper because these products appear to constitute patentably distinct inventions for the following reasons: Inventions A, B, C, D, E, F, G, and H are directed to sequences that are distinct both physically and functionally, and are not required one for the other. Invention A requires search and consideration of SEQ ID NO: 2, which is not required by any of the other Inventions. Invention B requires search and consideration of SEQ ID NO: 4, which is not

required by any of the other Inventions. Invention C requires search and consideration of SEQ ID NO: 5, which is not required by any of the other Inventions. Invention D requires search and consideration of SEQ ID NO: 11, which is not required by any of the other Inventions. Invention E requires search and consideration of SEQ ID NO: 14, which is not required by any of the other Inventions. Invention F requires search and consideration of SEQ ID NO: 17, which is not required by any of the other Inventions. Invention G requires search and consideration of SEQ ID NO: 18, which is not required by any of the other Inventions. Invention H requires search and consideration of SEQ ID NO: 19, which is not required by any of the other Inventions. Each sequence requires a separate search of the literature and sequence databases. A search and examination of an Invention as it pertains to all sequences would therefore present the examiner with an undue search burden.

**13. Applicant is advised that this is not a requirement to elect a species. Rather, this is a second restriction requirement superimposed upon the requirement to elect one group from I-VIII. In order to be fully responsive, Applicant must elect one group from I-VIII and one group from A-H.**

14. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

15. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1647

16. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

*Elizabeth C. Bernmere*

CJN  
February 20<sup>th</sup>, 2003